Gossamer bio announces gb004 topline results from phase 2 shift-uc study in ulcerative colitis and provides corporate update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its phase 2 shift-uc study clinical trial studying gb004 in patients with mild-to-moderate active ulcerative colitis (uc). neither gb004 treatment arm met the primary or secondary endpoints at week 12. based on the
GOSS Ratings Summary
GOSS Quant Ranking